Skip to main content
    D

    Delcath Systems Inc (DCTH)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $19.87
    -0.68 (-3.31%)

    Market Cap: $714.89M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Delcath Systems Inc (DCTH) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Delcath Systems (DCTH) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Delcath Systems reported EPS of $0.17, above the -$0.10 estimate. It beat the EPS estimate in each of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    65%(17/26)
    Avg Surprise
    +32.01%
    Streak
    8 Q

    Upcoming Estimates

    Reports Feb 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.11
    Range-$0.18 - -$0.02
    8 analysts
    Revenue Consensus
    $27.60M
    Range$25.73M - $28.98M
    8 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.01
    Range-$0.01 - -$0.01
    1 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.06-116.7%
    60d ago-$0.04+75.0%
    30d ago-$0.04+75.0%
    7d ago-$0.04+75.0%
    Current-$0.01
    Revenue Consensus
    $32.20M
    Range$31.90M - $32.50M
    2 analysts

    Next Report

    DCTH has an expected report date of Feb 22, 2027.

    DCTH Earnings Call

    The latest DCTH earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 26 quarters below that had an estimate, DCTH beat 17, missed 7 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $35.10M, up 70.7% from $20.56M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.17-$0.10-$0.13 - -$0.04+270.00%Beat+750.0%40 up, 1 downNov 9, 2026$35.10M
    Jun 30, 2026$0.07-$0.16-$0.16 - -$0.05+143.75%Beat0.0%20 up, 3 downAug 6, 2026$29.13M
    Mar 31, 2026-$0.03-$0.09-$0.14 - -$0.01+66.67%Beat-200.0%50 up, 3 downMay 7, 2026$24.99M
    Dec 31, 2025-$0.05-$0.06-$0.09 - $0.04+16.67%BeatN/A50 up, 0 downFeb 26, 2026$20.73M
    Sep 30, 2025$0.02-$0.09-$0.09 - -$0.09+122.22%Beat-66.7%10 up, 1 downNov 4, 2025$20.56M
    Jun 30, 2025$0.07$0.03$0.00 - $0.07+133.33%BeatN/A50 up, 1 downAug 6, 2025$24.16M
    Mar 31, 2025$0.03$0.03-$0.04 - $0.10+15.38%BeatN/A50 up, 0 downMay 8, 2025$19.78M
    Dec 31, 2024-$0.11$0.01-$0.10 - $0.09N/AN/AN/A53 up, 0 downMar 6, 2025$15.10M
    Sep 30, 2024$0.06-$0.19-$0.58 - -$0.04+131.58%BeatN/A63 up, 0 downNov 8, 2024$11.20M
    Jun 30, 2024-$0.48-$0.34-$0.42 - -$0.24-41.18%MissN/A60 up, 0 downAug 5, 2024$7.77M
    Mar 31, 2024-$0.45-$0.45-$0.61 - -$0.370.00%In lineN/A40 up, 0 downMay 14, 2024$3.14M
    Dec 31, 2023-$0.48-$0.51-$0.67 - -$0.41+5.88%BeatN/A50 up, 0 downMar 26, 2024$539000
    Sep 30, 2023-$1.14-$0.49-$0.63 - -$0.44-132.65%MissN/A50 up, 0 downNov 13, 2023$434000
    Jun 30, 2023-$0.58-$0.66-$0.89 - -$0.44+12.12%BeatN/A31 up, 0 downAug 9, 2023$495000
    Mar 31, 2023-$0.77-$0.62-$0.90 - -$0.42-24.19%MissN/A50 up, 1 downMay 22, 2023$597000
    Dec 31, 2022-$0.86-$0.73-$0.90 - -$0.46-17.81%MissN/A50 up, 0 downMar 27, 2023$638000
    Sep 30, 2022-$0.92-$1.04-$1.16 - -$0.77+11.54%BeatN/A51 up, 0 downNov 8, 2022$906000
    Jun 30, 2022-$1.18-$1.01-$1.02 - -$0.89-16.83%MissN/A40 up, 1 downAug 8, 2022$797000
    Mar 31, 2022-$1.00-$0.86-$0.95 - -$0.73-16.28%MissN/A51 up, 0 downMay 10, 2022$378000
    Dec 31, 2021-$0.69-$1.01-$1.51 - -$0.72+31.68%BeatN/A50 up, 0 downMar 25, 2022$2.11M
    Sep 30, 2021-$0.94-$1.13-$1.46 - -$0.91+16.81%BeatN/A4N/ANov 9, 2021$522000
    Jun 30, 2021-$0.96-$1.06-$1.15 - -$0.77+9.43%BeatN/A4N/AAug 10, 2021$536000
    Mar 31, 2021-$1.04-$1.03-$1.04 - -$0.89-0.97%MissN/A2N/AMay 11, 2021$388000
    Dec 31, 2020-$0.60-$1.09-$1.39 - -$0.82+44.95%Beat-100.2%4N/AMar 31, 2021$507000
    Sep 30, 2020-$1.16-$2.11N/A+45.02%BeatN/AN/AN/ANov 11, 2020$466000
    Jun 30, 2020-$1.90-$2.00N/A+5.00%BeatN/AN/AN/AAug 13, 2020$379000
    Mar 31, 2020-$108.07-$108.07N/A0.00%In lineN/AN/AN/AMay 14, 2020$294000
    Dec 31, 2019$269.30N/AN/AN/AN/AN/AN/AN/AMar 25, 2020$518000
    Sep 30, 2019-$0.41N/AN/AN/AN/AN/AN/AN/ANov 14, 2019$380000
    Jun 30, 2019-$0.08N/AN/AN/AN/AN/AN/AN/AJul 17, 2019$412000
    Mar 31, 2019-$0.11N/AN/AN/AN/A-101.0%N/AN/AJun 14, 2019$270000
    Dec 31, 2018-$0.17N/AN/AN/AN/AN/AN/AN/AMar 13, 2019$1.02M
    Sep 30, 2018-$0.25N/AN/AN/AN/AN/AN/AN/ANov 13, 2018$824000
    Jun 30, 2018-$7.26N/AN/AN/AN/AN/AN/AN/AAug 15, 2018$858000
    Mar 31, 2018$10.91N/AN/AN/AN/AN/AN/AN/AMay 10, 2018$702000
    Dec 31, 2017-$380.17N/AN/AN/AN/AN/AN/AN/AMar 16, 2018$704000
    Sep 30, 2017-$4,493.76N/AN/AN/AN/AN/AN/AN/ANov 14, 2017$684000
    Jun 30, 2017-$1,347.43N/AN/AN/AN/AN/AN/AN/AAug 8, 2017$584000
    Mar 31, 2017-$43,922.48N/AN/AN/AN/AN/AN/AN/AMay 9, 2017$743000
    Dec 31, 2016-$1,000,000.00N/AN/AN/AN/AN/AN/AN/AMar 29, 2017$676000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.07, a profit after a loss of $0.98 per share the year before. It was -$4,000,000.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.07N/A
    Dec 31, 2024-$0.98N/A
    Dec 31, 2023-$2.97N/A
    Dec 31, 2022-$3.96N/A
    Dec 31, 2021-$3.63N/A
    Dec 31, 2020-$111.73-141.6%
    Dec 31, 2019$268.70+8218.9%
    Dec 31, 2018$3.23N/A
    Dec 31, 2017-$50,143.84N/A
    Dec 31, 2016-$4,000,000.00N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,200 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20263,20710
    2026Q1Mar 31, 20264,73912
    2025Q4Dec 31, 20255,78711
    2025Q3Sep 30, 20254,02912
    2025Q2Jun 30, 20255,87713
    2025Q1Mar 31, 20255,79812
    2024Q4Dec 31, 20246,27113
    2024Q3Sep 30, 20245,47512

    2026Q3 Earnings Call

    Opening remarks

    David Hoffman General Counsel Thank you, and welcome to Delcath Systems' third quarter 2026 earnings call. With me on the call are Gerard Michel, Chief Executive Officer; Sandra Pennell, Chief Financial Officer; Kevin Muir, Chief Commercial Officer; Vojo Vukovic, Chief Medical Officer; and Martha Rook, Chief Operating Officer. This statement is made pursuant to the safe harbor for forward-looking statements described in the Private Securities Litigation Reform Act of 1995. The statements made on this call, with the exception of historical facts, may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the company believes that expectations and assumptions reflected in these forward-looking statements are reasonable, it makes no assurance that such expectations will prove to have been correct. Actual results may differ in a material manner from those expressed or implied in forward-looking statements due to various risks and uncertainties. For a discussion of such risks and uncertainties, please see the risk factors detailed in the company's annual report on Form 10-K, quarterly reports on Form 10-Q, and other reports that the company files from time to time with the Securities and Exchange Commission. Any forward-looking statements included in this call are made only as of the date of this call. We do not undertake any obligation to update or supplement any forward-looking statements to reflect subsequent knowledge, events, or circumstances. We will also discuss adjusted EBITDA, a non-GAAP financial measure. This measure should not be considered a substitute for GAAP results. A reconciliation to net income is included in our earnings release. The third quarter 2026 earnings release is available in the investor section of our website, along with additional details on our financial results and our latest SEC filings. We encourage you to review those materials. A recording of today's call will also be available on our website. Now I'll turn the call over to Gerard Michel. Gerard, please proceed.

    Gerard Michel CEO Thank you, David, and good morning. Delcath's record third quarter of $35.1 million in revenue, up 71% in the third quarter of 2025, reflects the growing adoption of HEPZATO KIT and the hard work of both the Delcath and physician treatment teams. Just as importantly, we are delivering positive operating cash flow, which gives us the flexibility to support investment in both the treatment networks and ongoing research that will expand the platform. The growth and profitability were driven by strong new patient starts for the quarter at approximately 0.6 new patient starts per site per month. We now have 33 active treatment centers in the U.S. Since our last update, we have added the University of Nebraska and AdventHealth.

    Frequently Asked Questions About DCTH

    When is Delcath Systems's next earnings date?

    Delcath Systems's next earnings report is expected for Feb 22, 2027.

    Did DCTH beat earnings estimates last quarter?

    Yes. Delcath Systems reported EPS of $0.17 for the quarter ended Sep 30, 2026, above the -$0.10 estimate, a 270.00% surprise.

    What EPS do analysts expect from DCTH next quarter?

    The consensus EPS estimate for Delcath Systems for the quarter ending Dec 31, 2026 is -$0.11 from 8 analysts, with estimates from -$0.18 to -$0.02.

    How often does DCTH beat earnings estimates?

    Delcath Systems beat the EPS estimate in each of the 8 most recent quarters that had an estimate, with an average surprise of +112.45%.